CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 33 enrolled
Drug / intervention
Methotrexate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00932113
NCT00932113Phase 4Completed
CompareCT.gov

An Investigator-Initiated, Assessor Blinded, Randomized Study Comparing the Mechanism of Action of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis.

Tufts Medical Center·interventional·Posted Jul 3, 2009·Updated Aug 31, 2017

In Brief

A Phase 4 clinical trial evaluating Methotrexate and Adalimumab (Humira) for Psoriasis. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The objective of this study is to compare the mechanism of action between adalimumab and methotrexate in subjects with psoriasis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJul 3, 2009
Enrollment StartJun 1, 2009
Primary CompletionDec 1, 2011
Study CompletionMay 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 17.0 years ago

Interventions

Methotrexatedrug

2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks. Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study.

Adalimumab (Humira)drug

2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.